학술논문
POSTER: TCL-275 Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients With Relapsed or Refractory T-Cell Lymphoma (TCL) With Survival Analysis
Document Type
Abstract
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S215-S215
Subject
Language
ISSN
2152-2650